Kornimate/medical-research-clean huggingface dataset:
analgesics in the pre-hospital setting: implications on hemorrhage tolerance - sufentanil

Conditions: Healthy

Summary: this study will examine how sufentanil (a commonly used pain medication) will alter responses to simulated blood loss in humans. to simulate blood loss in the research laboratory, participants will complete a test with their lower body in a custom-designed vacuum chamber for a brief period of time.

pain management on the battlefield is critical for the wellbeing of the soldier. given that a hemorrhagic injury on the battlefield is virtually always associated with pain, it is paramount that the selected pain medication does not disrupt appropriate physiological mechanisms that are beneficial towards the maintenance of blood pressure and vital organ blood flow during that hemorrhagic insult. current guidelines for the selection of pain medications of a hemorrhaging soldier are based upon limited scientific evidence, with the vast majority of supporting studies being conducted on anesthetized animals. thus, the interaction between hemorrhagic shock and pain medications commonly employed on the battlefield is yet to be determined in the conscious humans. this study will test the hypothesis that sufentanil will impair the capacity for a conscious human to tolerate a hemorrhagic insult. the obtained data will provide the necessary scientific evidence in humans to support the committee on tactical combat casualty care (cotccc) guidelines on the analgesic of choice for moderate to severe injuries where the casualty is in hemorrhagic shock. notably, such data will identify the analgesic that least compromises a human's ability to tolerate a hemorrhagic insult, ultimately providing critical information to the combat medic on which analgesic should be employed for such an injury.

Eligibility criteria:
inclusion criteria: * 18-45 years of age * healthy * non-obese (body mass index less than 30 kg/m2) * body mass greater than or equal to 65 kg * speak english exclusion criteria: * subjects not in the defined age range * subjects who have cardiac, respiratory, neurological and/or metabolic illnesses * any known history of renal or hepatic insufficiency/disease * pregnancy or breast feeding * body mass less than 65 kg * current smokers, as well as individuals who regularly smoked within the past 3 years * subjects who cannot speak or read english * positive urine drug screen * currently taking pain modifying medication(s)
jazz music and mindfulness for chronic pain

Conditions: Chronic Pain

Summary: chronic pain, including spinal pain and osteoarthritis, is the leading cause of years lived with disability world-wide and the costliest health condition in the u.s. today. compounding these concerns, opioid analgesics remain the primary pharmacological treatment for chronic pain. an estimated 21-29% of chronic pain patients receiving long-term opioid therapy develop opioid misuse, and opioid misuse portends addiction and overdose. clearly, chronic pain patients need better, non-addictive treatment options designed to reverse the downward spiral of chronic pain.

group assignments participants will be randomized into one of three groups. 1. jazz group 1: participants in this group will watch an introduction to jazz appreciation video prior to the 4-week intervention. 2. jazz group 2 (mindful jazz) group: participants in this group will watch a video on mindful listening to jazz. 3. music waitlist group: participants in this group will serve as a control and will not receive any intervention until the study is completed. they will complete a baseline survey and a follow-up survey at four weeks. some videos will be sent to this group after the study is completed, without tracking their usage. intervention all groups will complete a baseline and 4-week follow-up survey. participants in jazz group 1 and jazz group 2 will engage in daily listening 4-week intervention.they will have access to electronic audio recordings, with the order of listening labeled for each day. it is up to them if they want to listen to the daily recordings.

Eligibility criteria:
inclusion criteria: 1. are 18+ 2. live in the us 3. are an english-proficient adult with a chronic pain diagnosis (no restrictions placed on type) 4. have a pain rating of four or greater in average pain on a 0-10 numeric rating scale in the preceding week 5. have had pain for at least 3 months and for at least 15 days in the preceding 30 days 6. have moderate to severe anxiety based on gad-7 exclusion criteria: 1. are currently using or have used prescription opioids in the past 3 months to minimize a known treatment confound and increase sample homogeneity 2. have a current cancer diagnosis
dose-finding study of favipiravir in the treatment of uncomplicated influenza

Conditions: Influenza

Summary: this is a phase 2, randomized, double-blind, placebo-controlled multicenter study evaluating the efficacy and safety of two doses of favipiravir in adult patients with uncomplicated influenza.

this is a phase 2, randomized, double-blind, placebo-controlled, multicenter study designed to evaluate the efficacy and safety of a 5-day regimen of favipiravir in influenza patients aged 20-80 years. enrolled patients will be randomly assigned to 1 of 3 parallel treatment dose groups:placebo; low-dose favipiravir (1000 mg favipiravir bid for 1 day, followed by 400 mg favipiravir bid for 4 days); high-dose favipiravir (1200 mg favipiravir bid for 1 day, followed by 800 mg favipiravir bid for 4 days).

Eligibility criteria:
inclusion criteria: 1. patients who test positive for influenza a or b by a commercially available rapid antigen test (rat) of the nasopharynx. a patient with a negative rat result may still enroll if the sponsor and investigator agree that there is a known influenza outbreak circulating in the community. 2. patients ≥ 20 but \< 65 years of age with a temperature (oral) of 100.4°f (38.0°c) or more; patients ≥ 65 years of age with a temperature (oral) of 100.0°f (37.8°c) or more at the first visit, or in the 6 hours prior if antipyretics were taken. 3. patients with 2 or more of the following symptoms (moderate to severe in intensity) at the time of enrollment: * cough * sore throat * headache * nasal congestion * feeling feverish * body aches and pains * fatigue (tiredness) exclusion criteria: 1. patients who have had influenza symptoms or fever (i.e., one of the symptoms listed under the inclusion criteria) for 36 hours or more prior to study screening. 2. patients who have underlying chronic respiratory disease (e.g., chronic obstructive pulmonary disease \[copd\], chronic bronchitis, diffuse panbronchiolitis, bronchiectasis, pulmonary emphysema, pulmonary fibrosis, bronchial asthma, or old tuberculosis). 3. patients who at the beginning of the study are suspected of having bacterial respiratory infection (i.e., expectoration of purulent or mucopurulent sputum and/or infiltrate in lung in a chest x-ray, etc.). 4. patients who have serious chronic diseases. for example, patients with hiv, cancer (i.e., requiring chemotherapy within the preceding 6 months), cirrhosis (end-stage), and/or unstable renal, cardiac, pulmonary, neurologic, vascular, or endocrinologic disease states requiring medication dose adjustments within the last 30 days.

Keywords: influenza
crossmodal learning in therapeutic processes (task 2-2)

Conditions: Sensory Ataxia

Summary: interventional study of the effects of vibro-tactile feedback on behavioral deficits and learning during motor training in patients with sensory ataxia.


Eligibility criteria:
inclusion criteria: * electrophysiological diagnosis of sensory ataxia * age \>= 18, \<=80 * existing declaration of consent exclusion criteria: * pregnancy * lacking capacity for consent

Keywords: vibro-tactile stimulation neurorehabilitation ataxia
a new mouthwash on reducing dental plaque and helping prevent gum problems

Conditions: Plaque; Gum Disease

Summary: this 6-month clinical study was designed to investigate clinical efficacy on plaque and gingivitis for the meridol base mouthwash containing 0.2% zinc lactate, 0.17% amine fluoride and 0.0275% sodium fluoride as compared to a negative control mouthwash containing 0.057% sodium fluoride after 3 and 6 months of product use.


Eligibility criteria:
inclusion criteria: * subjects, ages 18-70, inclusive. * availability for the six-month duration of the clinical research study. * good general health. * initial gingivitis index of at least 1.0 as determined by the use of the loe-silness gingival index. * initial plaque index of at least 1.5 as determined by the use of the quigley-hein plaque index. * signed informed consent form exclusion criteria: * presence of orthodontic bands. * tumor(s) of the soft or hard tissues of the oral cavity. * advanced periodontal disease (purulent exudate, tooth mobility, and/or extensive loss of periodontal attachment or alveolar bone). * five or more carious lesions requiring immediate restorative treatment. * antibiotic use any time during the one-month period prior to entry into the study. * participation in any other clinical study or test panel within the one month prior to entry into the study. * dental prophylaxis during the past two weeks prior to baseline examinations. * history of allergies to oral care/personal care consumer products or their ingredients. * on any prescription medicines that might interfere with the study outcome. * an existing medical condition that prohibits eating or drinking for periods up to 4 hours. * history of alcohol or drug abuse. * self-reported pregnant or lactating subjects
multiple ascending dose study of bms-929075 in hepatitis c virus (hcv) infected patients

Conditions: Chronic Hepatitis C

Summary: the purpose of this study is to determine the change from baseline in hcv ribonucleic acid (rna) on day 4 following three days of dosing with bms-929075 in chronically genotype subtype 1a and 1b hcv infected subjects


Eligibility criteria:
inclusion criteria: * men and women, ages 18 to 65 years, inclusive * subjects who are naive to hcv treatment, defined as no previous exposure to an interferon (ifn), ribavirin (rbv); or any hcv-specific direct acting antiviral or experimental therapy * hcv genotype 1a or 1b only * hcv rna viral load of ≥ 100,000 iu/ml * have one of the following: i) documented fibrotest score of ≤ 0.72 and ast to platelet ratio index (apri) ≤ 2; or ii) documented liver biopsy within 12 months preceding day 1 showing absence of cirrhosis * body mass index (bmi) of 18.0 to 35.0 kg/m2, inclusive exclusion criteria: * any significant acute or chronic medical illness * history of adrenal gland disease, including but not limited to adrenal insufficiency or cushing's syndrome * current or recent (within 3 months of study drug administration) gastrointestinal disease * any major surgery within 4 weeks of study drug administration * any gastrointestinal surgery that could impact upon the absorption of study drug * positive for hepatitis b surface antigen (hbsag) * positive for human immunodeficiency virus (hiv) -1 and/or -2 antibodies * smoking \> 10 cigarettes per day * alanine aminotransferase (alt) or aspartate aminotransferase (ast) \> 5x upper limit of normal (uln) * total bilirubin ≥ 1.5x uln * hemoglobin \< 10 g/dl * platelets \< 75,000 cell/μl * alc (absolute lymphocyte count) \< 1000 cell/μl * creatinine clearance (as estimated by method of cockcroft and gault) less than 60 ml/min
evaluation of qdot micro™ catheter for pulmonary vein isolation in subjects with paroxysmal atrial fibrillation

Conditions: Paroxysmal Atrial Fibrillation

Summary: prospective, non-randomized, pre-market clinical evaluation of the qdot micro™ catheter to demonstrate the safety and effectiveness when compared to an historical control performance goal.

prospective, non-randomized, pre-market clinical evaluation of the qdot micro™ catheter to demonstrate the safety and effectiveness when compared to an historical control performance goal. the trial has two arms: main arm and second arm (variable flow). the main arm will enroll 185 subjects and second arm will enroll 92 subjects.

Eligibility criteria:
key inclusion criteria: * symptomatic paroxysmal af with one electrocardiographically documented af episode within 6 months prior to enrollment and a a physician's note indicating recurrent self-terminating af within 7 days . documentation may include electrocardiogram (ecg); transtelephonic monitoring (ttm), holter monitor or telemetry strip. * failed at least one class i or class iii antiarrhythmic drug as evidenced by recurrent symptomatic af, contraindicated, or intolerable to the aad. * age 18 years or older. key exclusion criteria: * previous surgical or catheter ablation for atrial fibrillation. * af secondary to electrolyte imbalance, thyroid disease, or reversible or non-cardiac cause. * previously diagnosed with persistent or long-standing persistent af and/or continuous af \> 7 days. * valve repair or replacement or presence of a prosthetic valve. * cabg surgery within the past 6 months (180 days). * any carotid stenting or endarterectomy within the past 6 months. * coronary artery bypass grafting, cardiac surgery, or valvular cardiac surgical procedure within the past 6 months. * documented left atrium (la) thrombus within 1 day prior to the index procedure. * documented la size \> 50 mm. * documented lvef \< 40%. * contraindication to anticoagulation (e.g., heparin). * mi/pci within the past 2 months. * documented thromboembolic event (including transient ischemic attack) within the past 12 months. * uncontrolled heart failure or new york heart association (nyha) function class iii or iv. * awaiting cardiac transplantation or other cardiac surgery within the next 12 months. * presence of implanted pacemaker or implantable cardioverter defibrillator (icd). * women who are pregnant, lactating, or who are of child bearing age and plan on becoming pregnant during the course of the clinical investigation.
effects of local vibrations program of dorsiflexor muscles on neuromotor recovery in subacute stroke patients.

Conditions: Stroke Rehabilitation

Summary: the aim of the vibration intervention proposed in the current study is to allow a better neuromotor recovery in subacute stroke patients when compared with standard rehabilitation alone. these last years, it has been proven that the solicitation of a muscle using vibrations may lead to positive effects on the neuromuscular function. thus, the aim of the current study is to assess if the addition to a standard rehabilitation program of local vibrations sessions of the dorsiflexor muscles of the paretic limb of stroke patients may allow a better recovery of walking speed (primary outcome). one group using vibrations (i.e. experimental group) and one group with sham vibration (i.e. control group) will take part to this study.


Eligibility criteria:
inclusion criteria: * stroke patients in subacute rehabilitation phase (between 14 days and 3 months post-stroke) * first hemispheric, ischemic or hemorrhagic stroke * lower-limb deficiency with an initial motor testing \< 4 according to the mrc scale * no neurological history with functional impact other than stroke * having received informed information about the study and having signed the written consent * affiliated or entitled to a social security scheme. exclusion criteria: * multiple stroke * other neurological, cognitive or psychiatric conditions * orthopedic ankle history compromising measurements * botulinum toxin injected in the lower limb prior the study protocol * patient with a skin lesion close to the site for the placement of the stimulator * patient under tutorship or curatorship

Keywords: local vibration stroke motor recovery walking speed gait
g-csf and prp in patients with recurrent implantation failure

Conditions: Infertility,Female

Summary: the aim of this randomized controlled trial is to determine whether granulocyte colony-stimulating factor and platelet-rich plasma can be used to enhance the ivf-et outcomes in patients with recurrent implantation failure


Eligibility criteria:
inclusion criteria: • patients with history of three or more unsuccessful ivf-et cycles with at least 2 good quality embryos transferred exclusion criteria: * endometriosis * uterine anomalies * asherman syndrome

Keywords: ivf platelet-rich plasma granulocyte colony-stimulating factor recurrent implantation failure
differentiation of upper and lower respiratory tract infections using automated lung sound analysis with lungpass device

Conditions: Acute Respiratory Tract Infection

Summary: this observational study evaluates whether lung sound analysis with lungpass device can be used to differentiate upper and lower respiratory tract infections (urti and lrti)

this is a prospective observational study comprised patients presenting with acute respiratory tract infection symptoms in primary care settings. patients will undergo routine clinical examination including lung auscultation with conventional stethoscope and lungpass device. moreover, symptoms and anamnesis data, result of diagnostic questionnaire from the lungpass app, complete blood count, c-reactive protein, procalcitonin (pct) level, sars-cov-2 pcr test and x-ray chest examination or ct chest (in case of preliminary clinical suspicion of lrti). patients will be followed up within 5-7 days and at the end of the disease in person or by phone for clinical course of the disease assessment to confirm the final diagnosis (urti or lrti). final diagnosis will be considered as gold standard for accuracy assessment.

Eligibility criteria:
inclusion criteria: * adults (over 18 years) and children (3-18 years) of both sexes; * patients able and willing to sign an informed consent to participate in the study (parents of children younger than 18 years old will be allowed to give an informed consent on behalf of their children). * patients presenting with a new onset of at least two of listed acute respiratory tract infection symptoms within the last 5 days: cough, purulent sputum, breathlessness, core temperature above 38°c. * patients who first visit a gp with these symptoms within the first 5 days from the onset of symptoms and was not previously treated with antibiotics during the last month. exclusion criteria: * age up to 3 years; * patient refusal to participate in the study (or patients' parents); * children under full state care (orphans, children left without parental care); * treatment with antibiotics during the last month; * patients with subcutaneous emphysema, with damaged skin on the surface of the chest, with drainage in the pleural space, patients undergoing mechanical ventilation; * presence of other known chronic lung conditions such as asthma, copd, tuberculosis, cystic fibrosis or bronchiectasis; * mental illness, other known acute diseases or known chronic decompensated diseases, such as a known active malignancy or severe heart failure. * other known ongoing infection.

Keywords: lung sound analysis upper respiratory truct infections lower respiratory truct infections
effects of motivational interviewing in prison

Conditions: Alcohol Abuse

Summary: motivational interviewing (mi) is a communication style demonstrated to decrease drug and alcohol use. a five session mi intervention (bsf) was implemented in the swedish correctional system. the intervention was delivered by counsellors with workshop only mi training (bsf) or by counsellors with workshop mi training followed by peer group supervision based on audio taped feedback (bsf+). aim was to examine whether bsf in prisons reduces drug and alcohol use more effectively than interviews conducted according to the usual planning interview routine (upi).


Eligibility criteria:
inclusion criteria: * born between 01-01-1954 and 31-12-1984; * conditional release no later than 30-06-2005 (this was extended to 19-09-2005 and again to 31-03-2006); * swedish or norwegian speaker; * not having previously received bsf in remand or any other prison; * heavy use of alcohol or drugs, measured by the standard prison and probation system: 1= occasional use; 2= heavy use; * asi interview at intake; * no order for deportation after release from prison exclusion criteria: -

Keywords: inmates with heavy use of alcohol or drugs
study to analyze the efficacy of acute intake with a β-alanine supplement in recreational cyclists

Conditions: Beta Alanine Supplementation

Summary: randomized, controlled, double-blind, single-center, double-blind clinical trial with three parallel arms depending on the product consumed (experimental product dose 1 and dose 2 and placebo product) to measure the efficacy of a sustained release beta alanine on physiological physical performance efficacy in recreational cyclists.

subjects meeting the selection criteria will be randomly assigned to each of the study groups (investigational product dose 1 or dose 2, or placebo, depending on the group to which they have been assigned). the product to be consumed is beta alanine. participants will consume the product for 1 day. they will have to take four intakes every hour and a quarter, on the same day. the study subjects will have to make 2 visits to the laboratory. in the first one, they will have to perform a 10-minute time trial, without consumption. in the second visit, they will perform the same performance test but with acute consumption of the product. their physical and physiological performance will be evaluated. the two tests will be separated by 7 days.

Eligibility criteria:
inclusion criteria: * male cyclists with more than two years of cycling experience. * perform tests without fatigue. * road bike training at least twice a week. exclusion criteria: * participants with chronic illness. * have a long-term injury that prevents you from training in the previous month. * inability to understand informed consent. * have consumed beta alanine in the three years prior to the start of the study. * consumption of other supplements that may alter performance.

Keywords: acute effect beta alanine
analysis of articular biomarkers from osteoarthritic thumb basal joints

Conditions: Osteoarthritis Thumb; Osteoarthritis, Knee; Metabolic Disease

Summary: the study project aims at examining molecular markers in synovial fluid, bone and articular cartilage from osteoarthritic thumb basal joints. the degradation of extracellular matrix (ecm) proteins in thumb basal joints will be evaluated in association to the metabolic profile of the patient, but we also aim to compare the ecm degradation and inflammatory profiles with articular cartilage degradation ecm profile from knee joints with osteoarthritis. a third aim is to evaluate associations between patient-reported hand function, pain, strength and range of thumb motion to analyses of synovial fluid.

patients scheduled for trapeziectomy on the basis of thumb basal joint osteoarthritis will be asked to participate. synovial fluid from the thumb basal joint is aspirated before the joint is opened. the trapezium bone and cartilage is harvested. blood samples to evaluated lipid profile and glucose intolerance is drawn. blood pressure and measurements of obesity is taken. patients are also examined at baseline and 1 year postop with grip strength, pinch strength, range of thumb motion and asked to fill in patient-rated outcome measures; quickdash and nrs pain.

Eligibility criteria:
inclusion criteria: * men and women age ≥ 25 years * radiologically confirmed and symptomatic thumb basal joint osteoarthritis (oa) planned for trapeziectomy exclusion criteria: * previous surgery to the affected thumb basal joint * post-traumatic thumb basal joint oa * rheumatoid arthritis or other chronic inflammatory arthritis, history of psoriasis affecting joints, gout or pseudogout * ongoing infection in the hand or wrist * inability to co-operate with the follow-up protocol or to assimilate information about the study protocol (language difficulties, severe psychiatric disorder, cognitive impairment, drug addiction) * systemic or intra-articular glucocorticoids or intraarticular platelet-rich plasma or hyaluronic acid injections in the affected joint within 3 months prior to enrollment